Literature DB >> 11012633

Angiocentric nasal T/natural killer cell lymphoma: a single centre study of prognostic factors in 108 patients.

A Avilés1, N R Díaz, N Neri, S Cleto, A Talavera.   

Abstract

Angiocentric T cell/natural killer (NK) nasal lymphoma remains a rare clinical presentation in North America and Europe but is more common in Asia and Latin America. We have reviewed 108 cases of angiocentric T/NK cell lymphoma of the nasal cavity with a view to establishing prognostic factors. Most patients were high or high intermediate clinical risk and had additional poor prognostic factors such as bulky disease, high levels of beta 2 microglobulin, advanced stage and multiple extranodal involvement. At 8 years, overall survival was 82%, 90% and 84% for low-intermediate, high-intermediate and high clinical, respectively. Disease free survival was very similar: 79%, 83% and 80%, respectively. Multivariate analysis did not identify any factor influencing overall survival and disease-free survival. There was no evidence that the international prognostic index (IPI) was applicable in these patients and it appears that angiocentric T/NK cell lymphoma is an independent prognostic factor itself.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11012633     DOI: 10.1046/j.1365-2257.2000.00307.x

Source DB:  PubMed          Journal:  Clin Lab Haematol        ISSN: 0141-9854


  21 in total

1.  Angiocentric lesions of the head and neck.

Authors:  Cynthia M Magro; Molly Dyrsen
Journal:  Head Neck Pathol       Date:  2008-05-27

Review 2.  Intracranial nasal natural killer/T-cell lymphoma: immunopathologically-confirmed case and review of literature.

Authors:  Neal Luther; Jeffrey P Greenfield; Amy Chadburn; Theodore H Schwartz
Journal:  J Neurooncol       Date:  2005-11       Impact factor: 4.130

3.  Treatment outcome of radiotherapy alone versus radiochemotherapy in early stage nasal natural killer/T-cell lymphoma.

Authors:  Hui-Hui Ma; Li-Ting Qian; Hai-Feng Pan; Lin Yang; Hong-Yan Zhang; Zhi-Hua Wang; Jun Ma; Yu-Fei Zhao; Jin Gao; Ai-Dong Wu
Journal:  Med Oncol       Date:  2009-08-15       Impact factor: 3.064

4.  Modified SMILE (mSMILE) and intensity-modulated radiotherapy (IMRT) for extranodal NK-T lymphoma nasal type in a single-center population.

Authors:  Paola Ghione; Shunan Qi; Brandon S Imber; Venkatraman Seshan; Alison Moskowitz; Natasha Galasso; Matthew Lunning; David Straus; Craig Sauter; Parastoo Dahi; Ahmet Dogan; Joachim Yahalom; Steven Horwitz
Journal:  Leuk Lymphoma       Date:  2020-08-26

5.  Nasal natural killer/T-cell lymphoma and its association with type "i"/XhoI loss strain Epstein-Barr virus in Chile.

Authors:  M E Cabrera; Y Eizuru; T Itoh; C Koriyama; Y Tashiro; S Ding; S Rey; S Akiba; A Corvalan
Journal:  J Clin Pathol       Date:  2006-06-14       Impact factor: 3.411

6.  p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: association with large cell morphology and advanced disease.

Authors:  L Quintanilla-Martinez; M Kremer; G Keller; M Nathrath; A Gamboa-Dominguez; A Meneses; L Luna-Contreras; A Cabras; H Hoefler; A Mohar; F Fend
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

7.  Combined therapy in untreated patients improves outcome in nasal NK/T lymphoma: results of a clinical trial.

Authors:  Agustin Avilés; Natividad Neri; Raúl Fernández; Judith Huerta-Guzmán; Maria-Jesus Nambo
Journal:  Med Oncol       Date:  2013-06-25       Impact factor: 3.064

8.  Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy.

Authors:  Agustin Avilés; Natividad Neri; Raúl Fernández; Angel Calva; Judith Huerta-Guzmán; M Jesús Nambo
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

Review 9.  Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment.

Authors:  Holbrook Kohrt; Ranjana Advani
Journal:  Leuk Lymphoma       Date:  2009-11

10.  Primary intestinal extranodal natural killer/T-cell lymphoma, nasal type: A case report.

Authors:  Bao-Long Dong; Xiao-Hua Dong; Hui-Qi Zhao; Peng Gao; Xiao-Jun Yang
Journal:  World J Clin Cases       Date:  2020-01-06       Impact factor: 1.337

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.